All In Biotech

Free tool

FAERS Monitor: Coartem

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022268 or its brand name (Coartem, Artemether, Lumefantrine). Reports on generic versions are filed under their own applications.

Reports

198

Serious

174

88% of reports

Hospitalization

61

Death reported

23

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pyrexia22
  • vomiting18
  • dyspnoea17
  • asthenia16
  • malaise13
  • malaria13
  • drug ineffective12
  • maternal exposure during pregnancy11
  • headache10
  • anaemia9
  • dizziness9
  • pain9
  • condition aggravated8
  • fatigue8
  • swelling face8

Reports by year received

View as table
YearReports
20062
20099
201019
201112
201211
20136
201412
201519
20168
201718
201818
201912
202013
202110
20227
20236
20243
20257
20266

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,961 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
malariaSignal131997.61175.023,543
maternal exposure during pregnancySignal1113.17.4112
swelling faceSignal813.16.678
pyrexiaSignal226.84.6104
anaemiaSignal95.02.625
astheniaSignal164.52.841
vomitingSignal184.12.640
dyspnoeaSignal173.22.024
malaiseSignal133.11.917
condition aggravatedSignal82.81.48
dizziness91.91.03
headache101.70.92
pain91.60.81
fatigue81.10.60
drug ineffective121.00.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.